Abstract
Re-myelination is one of the greatest challenges in the therapy of peripheral neuropathies (PN). Demyelinating conditions are a vast clinical problem affecting up to 20 million people in US alone, with more than $3.5 billion of healthcare expenditure and devastating consequences on the patients' quality of life. Pharmacological approaches for the treatment of diseases affecting the integr…